These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 16151647)

  • 1. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
    Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
    Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of soluble FAS, FAS ligand and tumour necrosis factor-alpha in patients with chronic HCV infection.
    Raghuraman S; Abraham P; Daniel HD; Ramakrishna BS; Sridharan G
    J Clin Virol; 2005 Sep; 34(1):63-70. PubMed ID: 16087126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble Fas and soluble Fas L levels in patients with acute pancreatitis.
    Endo S; Inoue Y; Fujino Y; Yamada Y; Sato N; Wakabayashi G; Sakamoto T; Ishikura H; Tanaka T; Inada K; Sato S
    Res Commun Mol Pathol Pharmacol; 2000; 108(3-4):179-86. PubMed ID: 11913710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble Fas and soluble Fas ligand levels in patients with acute hepatic failure.
    Nakae H; Narita K; Endo S
    J Crit Care; 2001 Jun; 16(2):59-63. PubMed ID: 11481600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
    Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
    Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
    Naumnik W; Izycki T; Ossolinska M; Chyczewska E
    Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
    Onalan G; Selam B; Baran Y; Cincik M; Onalan R; Gündüz U; Ural AU; Pabuccu R
    Hum Reprod; 2005 Sep; 20(9):2391-5. PubMed ID: 15932917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
    Konno R; Takano T; Sato S; Yajima A
    Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
    Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
    Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seasonal changes of proapoptotic soluble Fas ligand level in allergic rhinitis combined with asthma.
    Mezei G; Lévay M; Sepler Z; Héninger E; Kozma GT; Cserháti E
    Pediatr Allergy Immunol; 2006 Sep; 17(6):444-9. PubMed ID: 16925690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
    Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
    Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment.
    Pignataro L; Arisi E; Sambataro G; Corsi MM
    J Surg Oncol; 2003 Jun; 83(2):112-5. PubMed ID: 12772205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
    Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
    J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating soluble Fas concentration in breast cancer patients.
    Ueno T; Toi M; Tominaga T
    Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the maternal and umbilical vein serum sFas/sFasL system in pregnancies complicated by preeclampsia with intrauterine growth retardation.
    Laskowska M; Laskowska K; Leszczyńska-Gorzelak B; Oleszczuk J
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):155-9. PubMed ID: 16169656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
    Mizutani Y; Yoshida O; Bonavida B
    J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease.
    Enjoji M; Yamaguchi K; Nakashima M; Ohta S; Kotoh K; Fukushima M; Kuniyoshi M; Tanaka M; Nakamuta M; Watanabe T; Nawata H
    Liver Int; 2004 Aug; 24(4):330-4. PubMed ID: 15287856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HBV-DNA and sFas, sFasL concentrations in serum of healthy HBsAg carriers.
    Lapiński TW; Kowalczuk O; Prokopowicz D; Chyczewski L; Jaroszewicz J
    Rocz Akad Med Bialymst; 2005; 50():179-82. PubMed ID: 16358961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
    Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
    Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.